Destiny Pharma Limited is an established innovative clinical stage pharmaceutical company founded in 1997 to identify and generate high value pharmaceutical intellectual property.

The company is focused on the scientific discovery and clinical development of highly innovative antimicrobials, through to the point where products can be profitably on-licensed to the industry for exploitation.

Destiny Pharma is a well-managed company with a track record of innovation. The company selects projects on a strictly commercial basis and project manages these using world-class teams, assembled on a project-by-project basis, to undertake research and development.

Destiny Pharma's lead drug, XF-73, is in clinical development for the prevention of post-surgical Staphylococcal hospital infections and the company will license/partner for onward development and commercialisation of the technology.

The need for new antimicrobial drugs is well recognised by governments, and healthcare organisations around the world recognise the unique situation such drug development currently resides in and a number of incentives are being implemented to encourage industry to renew development in this area.